Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses RNAi Patents to MWG Biotech

NEW YORK, July 25 (GenomeWeb News) - Alnylam Pharmaceuticals has licensed its RNA interference patents to MWG Biotech, the company said today.

 

Under the non-exclusive license to Alnylam's Kreutzer-Limmer patent family, MWG is allowed to provide research products and services in RNA interference.

 

The patent family covers short interfering RNAs and their use in mammalian cells. To date, 14 companies have licensed the patents, including eight research tool providers, according to Alnylam. Last week, Sigma-Aldrich became a licensee.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.